1. Home
  2. PLBY vs PYXS Comparison

PLBY vs PYXS Comparison

Compare PLBY & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

N/A

Current Price

$1.25

Market Cap

123.4M

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

N/A

Current Price

$1.71

Market Cap

141.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PLBY
PYXS
Founded
1953
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
123.4M
141.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
PLBY
PYXS
Price
$1.25
$1.71
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$2.83
★ $8.88
AVG Volume (30 Days)
523.7K
★ 871.9K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 87.50
3.03
EPS
★ N/A
N/A
Revenue
★ $120,928,000.00
$13,858,000.00
Revenue This Year
$6.60
N/A
Revenue Next Year
$5.14
$14,188.99
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 4.13
N/A
52 Week Low
$0.95
$1.03
52 Week High
$2.75
$5.55

Technical Indicators

Market Signals
Indicator
PLBY
PYXS
Relative Strength Index (RSI) 75.07 36.08
Support Level $1.25 $1.59
Resistance Level $1.30 $1.84
Average True Range (ATR) 0.06 0.13
MACD 0.02 0.05
Stochastic Oscillator 91.53 24.53

Price Performance

Historical Comparison
PLBY
PYXS

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: